Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription

International Journal of Molecular Sciences
Sang-Seok OhKwang Dong Kim

Abstract

Tumor cell resistance to anti-cancer drugs is a major obstacle in tumor therapy. In this study, we investigated the mechanism of cordycepin-mediated resensitization to cisplatin in T24R2 cells, a T24-derived cell line. Treatment with cordycepin or cisplatin (2 μg/mL) alone failed to induce cell death in T24R2 cells, but combination treatment with these drugs significantly induced apoptosis through mitochondrial pathways, including depolarization of mitochondrial membranes, decrease in anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1, and increase in pro-apoptotic proteins Bak and Bax. High expression levels of MDR1 were the cause of cisplatin resistance in T24R2 cells, and cordycepin significantly reduced MDR1 expression through inhibition of MDR1 promoter activity. MDR1 promoter activity was dependent on transcription factor Ets-1 in T24R2 cells. Although correlation exists between MDR1 and Ets-1 expression in bladder cancer patients, active Ets-1, Thr38 phosphorylated form (pThr38), was critical to induce MDR1 expression. Cordycepin decreased pThr-38 Ets-1 levels and reduced MDR1 transcription, probably through its effects on PI3K signaling, inducing the resensitization of T24R2 cells to cisplatin. The results suggest that co...Continue Reading

References

Aug 3, 2001·The Journal of Biological Chemistry·J SampathJ D Schuetz
Oct 8, 2003·The Oncologist·Gregory D LeonardSusan E Bates
Aug 19, 2007·Current Topics in Medicinal Chemistry·John Yuan WangSara Wu
Jun 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·Mary L NelsonBarbara J Graves
Feb 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kevin G Chen, Branimir I Sikic
Mar 19, 2013·Frontiers in Pharmacology·Hiba Zahreddine, Katherine L B Borden
Oct 15, 2013·Life Sciences·Hardeep S TuliDharambir Kashyap
May 3, 2014·International Journal of Oncology·I Made Winarsa RumaMasakiyo Sakaguchi
Oct 9, 2014·Nucleic Acids Research·Joshua P PlotnikPeter C Hollenhorst
Dec 3, 2014·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Shang-Min ChouTang-Long Shen
Sep 24, 2015·Seminars in Cancer Biology·Jürgen Dittmer
Oct 30, 2016·Current Pharmaceutical Design·Angelika Dlugosz, Anna Janecka
Aug 19, 2017·Current Cancer Drug Targets·Xiaoqian YangXipeng Wang
Oct 17, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Song XuWenquan Zhou
Apr 13, 2018·Nature Reviews. Cancer·Robert W RobeyMichael M Gottesman
Aug 21, 2018·Current Pharmaceutical Design·Yuan LiLu Yu
Nov 10, 2018·Evidence-based Complementary and Alternative Medicine : ECAM·Su-Bin YuIn-Ryoung Kim

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
Assay
flow cytometry
transfection
Immunoprecipitation
PCR

Software Mentioned

cBioPortal
Scansite
FlowJo

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.